Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 34,500 shares, a decline of 31.7% from the September 30th total of 50,500 shares. Currently, 2.5% of the shares of the company are sold short. Based on an average daily trading volume, of 106,300 shares, the days-to-cover ratio is currently 0.3 days.
Insider Transactions at Vaccinex
In related news, Director Albert Friedberg bought 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were acquired at an average price of $6.15 per share, with a total value of $1,230,000.00. Following the completion of the transaction, the director now owns 762,415 shares of the company’s stock, valued at $4,688,852.25. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders bought 203,753 shares of company stock worth $1,247,255. 51.50% of the stock is owned by insiders.
Institutional Investors Weigh In On Vaccinex
An institutional investor recently raised its position in Vaccinex stock. AIGH Capital Management LLC raised its holdings in Vaccinex, Inc. (NASDAQ:VCNX – Free Report) by 86.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,958 shares of the company’s stock after buying an additional 50,593 shares during the quarter. AIGH Capital Management LLC owned 6.90% of Vaccinex worth $707,000 as of its most recent SEC filing. Institutional investors and hedge funds own 50.11% of the company’s stock.
Vaccinex Price Performance
Vaccinex (NASDAQ:VCNX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($3.10) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.
Vaccinex Company Profile
Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.
See Also
- Five stocks we like better than Vaccinex
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Inflation Risk Rising, Key Trades Investors Are Making Now
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 Oil Stocks to Watch Before Earnings Come Out
- Where to Find Earnings Call Transcripts
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.